Literature DB >> 21600239

Time course of prepulse inhibition disruption induced by dopamine agonists and NMDA antagonists: effects of drug administration regimen.

Ming Li1, Wei He, Jing Chen.   

Abstract

Prepulse inhibition (PPI) of acoustic startle response is impaired in patients with schizophrenia and in animals acutely treated with dopamine agonists and NMDA antagonists. In this study, we investigated the time course of PPI disruption induced by repeated amphetamine, quinpirole, phencyclidine (PCP), and dizocilpine (MK-801) treatment. We focused on how PPI disruption development was influenced by drug administration regimens, comparing a constant versus an escalating dosing regimen. Male Sprague-Dawley rats were repeatedly treated with amphetamine (1.25-5.0 mg/kg, or constant 5.0 mg/kg, sc), PCP (0.50-2.0 mg/kg, or constant 0.5, 1.0 or 2.0 mg/kg, sc), quinpirole (0.03-0.12 mg/kg, or constant 0.12 mg/kg, sc), MK-801 (0.025-0.10 mg/kg, or constant 0.10 mg/kg, sc) or vehicle (saline) and tested for PPI once daily for 6 consecutive days. When amphetamine 5.0 mg/kg or quinpirole 0.12 mg/kg was administrated on a constant dosing schedule, both drugs disrupted PPI upon acute administration, but had no effect after repeated treatment and testing (days 2-5). However, when amphetamine 5.0 mg/kg or quinpirole 0.12 mg/kg was preceded by two lower doses in an escalating dosing regimen, both drugs still disrupted PPI on days 5 and 6 when the constant amphetamine and quinpirole had no effect. For PCP and MK-801, repeated treatment under both regimens produced a stable and persistent disruption of PPI. Startle magnitude increased progressively and dose-dependently under both regimens for all drugs except for quinpirole, which caused a decrease. These results suggest that the drug dosing schedule, rather than the absolute amount of drug that an animal receives, has a greater impact on the development of PPI-disruptive effect of dopamine agonists than NMDA antagonists. Thus, in order to mimic the emerging process of PPI deficit with dopamine agonists, an escalating dosing regimen should be used.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21600239     DOI: 10.1016/j.pbb.2011.05.001

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  6 in total

1.  Behavioral and pharmacological validation of an integrated fear-potentiated startle and prepulse inhibition paradigm.

Authors:  Mengjiao Zhang; Ming Li
Journal:  Behav Brain Res       Date:  2016-04-06       Impact factor: 3.332

2.  Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of 'schizophrenia-like' behaviour in the rat.

Authors:  Philip L R Gaskin; Stephen P H Alexander; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

3.  Clozapine, but not olanzapine, disrupts conditioned avoidance response in rats by antagonizing 5-HT2A/2C receptors.

Authors:  Ming Li; Tao Sun; Alexa Mead
Journal:  J Neural Transm (Vienna)       Date:  2011-10-11       Impact factor: 3.575

4.  Adult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: a preclinical test in the phencyclidine hyperlocomotion model.

Authors:  Qing Shu; Gang Hu; Ming Li
Journal:  J Psychopharmacol       Date:  2013-11-20       Impact factor: 4.153

5.  Long-term impacts of adolescent risperidone treatment on behavioral responsiveness to olanzapine and clozapine in adulthood.

Authors:  Jing Qiao; Qinglin Zhang; Ming Li
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-10-16       Impact factor: 5.067

6.  Sensorimotor gating impairments induced by MK-801 treatment may be reduced by tolerance effect and by familiarization in monkeys.

Authors:  Patricia G Saletti; Rafael S Maior; Etsuro Hori; Hisao Nishijo; Carlos Tomaz
Journal:  Front Pharmacol       Date:  2015-09-22       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.